Clinical Trials Browser

Completed × INDUSTRY × HBI-8000 × Clear all

NCT02953652 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 2 Completed

55 enrolled 18 charts

Lymphoma, T-Cell, Peripheral

NCT02955589 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

Phase 2 Completed

23 enrolled 15 charts

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02718066 2023-11-09

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Phase 1/2 Completed

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02697552 2017-01-12

Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Phase 1 Completed

Lymphoma, Non-Hodgkin